The earnings call highlights significant revenue growth, gross margin expansion, and strategic achievements such as the increased in-network patient percentage and FDA study milestones. However, these positive aspects are tempered by ongoing net losses and increased operating expenses.

Company Guidance

During the Kestra Medical Technologies earnings call for the first quarter of fiscal year 2026, management provided updated guidance and highlighted several key metrics indicating strong growth and performance. The company reported a 52% year-over-year increase in revenue, reaching $19.4 million, driven by a 51% increase in prescriptions for the ASSURE system. The gross margin expanded to 45.7% from 32.9% in the prior year, marking the seventh consecutive quarter of gross margin improvement. Kestra's in-network patient mix rose to nearly 80%, contributing to a higher revenue per fitting. Operating expenses increased to $37.7 million, largely due to growth investments in commercial and revenue cycle resources. The company also raised its fiscal year 2026 revenue guidance to $88 million, a 47% increase from fiscal year 2025, with expectations of continued strong prescription growth and improvements in revenue cycle management.

Strong Revenue Growth

Revenue grew 52% year-over-year to $19.4 million, driven by a 51% increase in ASSURE system prescriptions.

Gross Margin Expansion

First quarter gross margin was 45.7%, up from 32.9% in the prior year period, marking the seventh consecutive quarter of gross margin expansion.

Increase in In-Network Patients

The percentage of fittings for patients with in-network benefits increased from approximately 70% at the time of IPO to nearly 80%.

FDA Post-Approval Study Milestone

Conclusion of enrollment in the FDA post-approval study for the ASSURE system, which will be the largest study ever published in the WCD category.

Guidance Increase

Fiscal year 2026 revenue guidance increased to $88 million, up 47% compared to fiscal year 2025, from previous guidance of $85 million.

Kestra Medical Technologies Ltd. (KMTS) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

KMTS Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Apr 20, 2026	2026 (Q3)	- / -	-1.25	―	―	―
Sep 11, 2025	2026 (Q1)	-0.61 / -0.50	-0.45	-11.11% (-0.05)	―
Jul 15, 2025	2025 (Q4)	-0.53 / -2.21	-0.49	-351.02% (-1.72)	―
Apr 14, 2025	2025 (Q3)	-0.60 / -1.25	-0.473	-164.27% (-0.78)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

KMTS Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Sep 11, 2025	$18.40	$21.83	+18.64%
Jul 15, 2025	$16.29	$15.35	-5.77%
Apr 14, 2025	$23.83	$24.13	+1.26%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Kestra Medical Technologies Ltd. (KMTS) report earnings?

Kestra Medical Technologies Ltd. (KMTS) is schdueled to report earning on Apr 20, 2026, After Close (Confirmed).

What is Kestra Medical Technologies Ltd. (KMTS) earnings time?

Kestra Medical Technologies Ltd. (KMTS) earnings time is at Apr 20, 2026, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is KMTS EPS forecast?

Currently, no data Available

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing